COVID-19: PHE laboratory assessments of molecular tests
PHE has undertaken rapid assessments of commercially provided diagnostic tests for SARS-CoV-2 nucleic acid detection with further evaluations ongoing.
Documents
Details
Public Health England (PHE) has undertaken rapid assessments of commercially provided diagnostic tests for SARS-CoV-2 nucleic acid detection with further evaluations ongoing.
Included here are:
- a summary report for the laboratory assessments of COVID molecular diagnostic tests undertaken by PHE and completed in the period February and April 2020
- a series of individual assay assessments
Updates to this page
Published 4 June 2020Last updated 22 February 2021 + show all updates
-
Added: 'Rapid assessment: BGI Real-Time Fluorescent RT-PCR kit for detecting 2019-nCoV'.
-
Added Rapid assessment of Biomerieux ARGENE® SARS-COV-2 R-GENE® real-time detection kit.
-
Added rapid assessment: careGENE N-CoV RT-PCR Kit.
-
Added rapid assessments: COVID-19 Plus RealAmp kit and GenMark ePlex SARS-CoV-2 test.
-
First published.